NewAmsterdam Pharma (NAMS) Assets (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Assets of $732.6 million for Q1 2026, down 4.76% sequentially from $769.3 million in Q4 2025, and down 10.48% YoY from $818.4 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Assets (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Assets for 6 years, with the latest figure at $732.6 million in Q1 2026.
- Quarterly Assets fell 10.48% year-over-year to $732.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $732.6 million (down 10.48% YoY) and the FY2025 annual result came in at $769.3 million, down 11.03% from the prior year.
- Assets declined to $732.6 million in Q1 2026 per NAMS's latest filing, from $769.3 million in the prior quarter.
- Over five years, Assets peaked at $864.6 million in Q4 2024 and troughed at $347.1 million in Q4 2023.
- A 5-year average of $630.3 million and a median of $637.5 million in 2022 frame the typical range for Assets.
- The sharpest annual moves came in 2022 and 2023: Assets jumped 693.03% in 2022, then slumped 36.0% in 2023.
- Over 5 years, Assets stood at $542.3 million in 2022, then plunged by 36.0% to $347.1 million in 2023, then surged by 149.1% to $864.6 million in 2024, then decreased by 11.03% to $769.3 million in 2025, then declined by 4.76% to $732.6 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $732.6 million, $769.3 million, and $786.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 704.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 704.45 Mn |
| Mar 31, 2026 | 732.64 Mn |
| Dec 31, 2025 | 769.28 Mn |
| Sep 30, 2025 | 786.43 Mn |
| Jun 30, 2025 | 815.11 Mn |
| Mar 31, 2025 | 818.41 Mn |
| Dec 31, 2024 | 864.62 Mn |
| Sep 30, 2024 | 439.19 Mn |
| Jun 30, 2024 | 446.69 Mn |
| Mar 31, 2024 | 488.46 Mn |
| Dec 31, 2023 | 347.10 Mn |
| Jun 30, 2023 | 512.99 Mn |
| Dec 31, 2022 | 542.35 Mn |
| Dec 31, 2021 | 68.39 Mn |